Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 25Lymphoma, Large B-Cell, Diffuse 24Burkitt Lymphoma 19Lymphoma, Follicular 14Lymphoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Neoplasms 8Lymphoma, Non-Hodgkin 8Lymphoma, B-Cell 6Recurrence 5Prostatic Neoplasms, Castration-Resistant 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Biphenotypic, Acute 4Ovarian Neoplasms 3Lymphoproliferative Disorders 3Lymphoma, T-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Prostate Cancer Metastatic 2Plasmablastic Lymphoma 2Multiple Myeloma 2Metastatic Castration-resistant Prostate Cancer 2Melanoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Enteropathy-Associated T-Cell Lymphoma 2

Interventions

Cyclophosphamide 7Biopsy 4mogamulizumab 3Specimen Handling 3Peripheral Blood Stem Cell Transplantation 3Etoposide 3ruxolitinib 2fludarabine phosphate 2fludarabine 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Prednisone 2Nivolumab 2Mycophenolic Acid 2Magnetic Resonance Spectroscopy 2Busulfan 2tofacitinib 1tazemetostat 1talimogene laherparepvec 1sodium-iodide symporter 1pembrolizumab 1hypericin 1cemiplimab 1belinostat 1X-Rays 1Vorinostat 1Transplantation 1Sirolimus 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Cutaneous × Prednisone × 90 days × Clear all
NCT07535710 2026-04-17

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma

Shanghai Jiao Tong University School of Medicine

Phase 1/2 Not yet recruiting
37 enrolled
DermatologicLymphoid

Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT05996185 2026-04-14

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Yale University

Phase 2 Recruiting
22 enrolled
DermatologicLymphoidOther hematologic neoplasm

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡